Article Text

Download PDFPDF

264 Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma
  1. Myles Dillon1,
  2. Lianjie Li1,
  3. Jeongsook Bang2,
  4. Nicholas Gaspar3,
  5. Jessica Kuhnert1,
  6. Nathalie Fiaschi1,
  7. Vladimir Jankovic1,
  8. Israel Lowy1,
  9. Gavin Thurston1,
  10. Glenn Kroog1,
  11. Kyoung Soo Ha3,
  12. Raquel Deering1 and
  13. Raquel Deering1
  1. 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  2. 2Sillajen Inc., Seoul, Korea, Republic of
  3. 3Sillajen Biotherapeutics, San Francisco, CA, USA


Background To better understand the immune stimulatory mechanisms of Oncolytic virus (OV), we evaluated the circulating OV-specific T cell response in patients during the course of OV therapy. Patients with histologically confirmed advanced clear cell renal cell carcinoma, who were naïve or refractory to prior systemic treatment and who had no prior treatment with immune checkpoint inhibitors, were treated with 4 weekly intravenous infusions of Pexa-Vec at 1 × 109 plaque forming units starting at Day -7 plus Cemiplimab (350 mg every 3 weeks) from Day 1. Radiographic assessments per RECIST 1.1 were performed centrally every 9 weeks from Day 1. Peripheral blood mononuclear cells (PBMCs) were collected and cryopreserved at baseline and 29 days post initial Pexa-Vec treatment.

Methods We performed functional IFNγ ELISPOT analysis on longitudinal PBMC samples using a custom panel of OV epitopes and culture conditions designed to measure existing OV-specific memory T cell cytolytic activity [1]. PBMC samples were tested for IFNγ release following stimulation with OV peptides using two different assay conditions: 1) measurement following direct ex vivo stimulation with OV peptides alone, and 2) measurement following 10 days of T cell expansion in the presence of OV peptides, T cell supportive cytokines (GM-CSF, IL-4, IL-7 and IL-15), and autologous dendritic cells. The number of OV-specific IFNγ spots was correlated with the clinical response and tumor regression.

Results In preliminary analyses, 8 of the 11 (72.7%) patients showed tumor burden reduction, 4 of whom had ≥30% confirmed reduction that qualify as RECIST1.1 PRs (figure 1 and 2). OV-specific IFNγ+ T cells were detected in only 3 out of 11 patients in the non-expanded ELISPOT culture conditions (figure 3A), but in 8 out of 11 patients when T cells were first expanded for 10 days in the presence of OV peptides prior to ELISPOT, which trended toward a correlation with the preliminary clinical response assessment (figure 3B). Prolonged stimulation with CMV, EBV and Influenza peptides did not show any correlation (R2 = 0.005), suggesting that the treatment and culture expansion influenced relevant OV-specific memory T cell proliferation.

Abstract 264 Figure 1

Tumor response and% change in tumor burdenPatients received 6 to 15 rounds of Cemiplimab at the time of data collection.*One patient who had Progressive Disease experienced significant regression of primary tumor but developed metastatic lesions.

Abstract 264 Figure 2

Tumor volume change in individual patientsPercentage of tumor volume change in individual patients over the course of treatment.

Abstract 264 Figure 3

Correlation between ELISPOT and tumor responseCorrelation between T-cell response (ELISPOT) and tumor volume change.PBMC sample detection range: 9-fold inscrease in the detection range of IFNγ producing cells up to 1000 SFC/2 × 105 cells, (3B) from a detection range of fewer than 110 SFC/2 × 105 cells (3A).Pre-expanded ELISPOT revealed a trend of correlation between CD8+ T cell response and tumor volume reduction even at an early sample collection time point (Day 29) with R2=0.3031 and p-value = 0.0793.

Conclusions These results suggest that OV-specific T cell responses can be induced by OV therapy. In addition, 10-day expansion of low levels of OV-specific circulating T cells can amplify signals in ELISPOT analysis and might enable systemic tracking of patient responses in blood samples collected at early time points. The observed CD8+ T cell response to oncolytic vaccinia virus in patients supports the rationale for combination treatment with Pexa-Vec and immune checkpoint inhibitors.

Acknowledgements Sun Young Rha, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of KoreaJamie Merchan, University of Miami Health System, Miami, FL, USASung Yong Oh, Dong-A University Hospital, Busan, Republic of KoreaChan Kim, Cha University Bundang Medical Center, Seongnam, Republic of KoreaWoo Kyun Bae, Chonnam National University Hwasun Hospital, Hwasun, Republic of KoreaHyun Woo Lee, Ajou University Hospital, Suwon, Republic of Korea.

Trial Registration NCT03294083

Ethics Approval The study was approved by University of Miami Institutional Reivew Board, approval number 20180055.


  1. Dillon M, Jeong S, De Silva N, et al. Tracking oncolytic virus-specific CD8+ T cells with epitope-based, HLA-agnostic peptides in a renal cell carcinoma clinical trial. CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE 2019. Abstract #A067

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.